research Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata
Ifidancitinib, a JAK inhibitor, effectively regrows hair in mice with alopecia by tiring out harmful T cells.
Search
for
Sort by
Research
330-360 / 1000+ resultsresearch Systemic Tofacitinib in Alopecia Areata: A Single Center Retrospective Descriptive Cohort Study
Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.
research Sisaipho alopecia areata treated with tofacitinib and oral minoxidil
Tofacitinib and oral minoxidil may help treat Sisaipho alopecia areata.
research 42380 FFA and Personal Care Product Use, An Investigation into Hair Styling and Stratified Gender Analysis of Facial Sunscreen and Moisturizer: A Systematic Review and Meta-Analysis
Sunscreen use is linked to frontal fibrosing alopecia, especially in males.
research Therapeutic potential of oral tofacitinib in alopecia areata: a retrospective study
Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
research A Novel Hope for Alopecia Totalis Patients: Case Report
Tofacitinib may effectively regrow hair in alopecia totalis patients.
research Clinicopathological characteristics and treatment outcomes of fibrosing alopecia in a pattern distribution: A retrospective cohort study
Early treatment of fibrosing alopecia in a pattern distribution may improve outcomes.
research PCA: A tFNA-based targeted nucleic acid nanocomposite hydrogel for the treatment of androgenetic alopecia through the promotion of angiogenesis and hair follicle stem cell proliferation
PCA hydrogel promotes hair growth by enhancing blood vessel formation and hair follicle stem cell activity.
research ISID0199 – Computer vision AI-based androgenetic alopecia analysis using a novel mobile web app.
research Low-dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost-saving regimen
Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
research Comparison of two methods for isolation and culture of human foreskin fibroblasts.
EDM is better for isolating and growing human foreskin fibroblasts, and PPP helps repair UVB damage.
research Frontal fibrosing alopecia: a survey in 16 patients
The study found that Frontal Fibrosing Alopecia affects a broader age range of women and early treatment can help stop hair loss.
research Tofacitinib citrate alleviates alopecia universalis symptoms in recent case study
Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.
research Frontal fibrosing alopecia: a retrospective clinical review of 62 patients with treatment outcome and long-term follow-up
The treatment helped reduce symptoms and stabilize the hairline in most patients with Frontal Fibrosing Alopecia, but hair regrowth was limited.
research FGF signaling for hair cycle resting phase alleviates radiation alopecia
FGF18 treatment during hair's resting phase can protect against hair loss from radiation.
research Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study
Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
research 1322 Molecular profiling of frontal fibrosing alopecia (FFA) reveals TH1 and JAK-STAT up-regulation with no suppression of hair keratins
Frontal fibrosing alopecia shows increased inflammation and JAK-STAT pathway activity without reduced hair proteins.
research 128 Analysis of mice skin distribution using MALDI-MSI after subcutaneous injections of a potent novel peptide hair growth promoter, FOL-005
FOL-005, a hair growth promoter, acts locally on mouse skin where injected and could be a promising hair loss treatment.
research Excellent response to tofacitinib treatment in a patient with alopecia universalis
A patient with complete hair loss regrew all her hair using tofacitinib.
research Tofacitinib for the Treatment of Three Immune-mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata
Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
research Fibrosing Frontal Alopecia: A comprehensive study to understand its etiology
More research is needed to better understand and treat Fibrosing Frontal Alopecia.
research Tofacitinib in the Recalcitrant Cases of Alopecia Areata: A Pilot Study
Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.
research Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib
Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.
research Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata
Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
research Real-World Effectiveness of JAK Inhibitors for Alopecia Totalis and Alopecia Universalis: A Single-Center Experience
JAK inhibitors are effective and safe for treating severe alopecia areata.
research 43237 Infantile Perianal Pyramidal Protrusion (IPPP): A Retrospective Review of 28 Patients
Recognizing IPPP is crucial to prevent misdiagnosis and unnecessary treatments.
research MP11-05 THE UROLOGIC IMPACT OF LONG-TERM FINASTERIDE-1 MG USE FOR ANDROGENIC ALOPECIA: A MATCHED-COHORT DATABASE ANALYSIS
Long-term finasteride use may lower prostate cancer risk but increase the need for erectile dysfunction medication.
research Fish Acellular Dermal Matrix Promotes Repair of Full‐Thickness Skin Defects in Mice and Bama Pigs
Tilapia skin matrix effectively aids skin wound healing and is a promising option for clinical use.
research Efficacy and safety of tofacitinib in pediatric patients with alopecia areata: A prospective cohort study
Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
research Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors
The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.